TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
University of Kentucky researchers reported that temporarily depleting about 87% of microglia restored more than two hours of sleep per day in mice with Alzheimer’s-like brain changes, without removing amyloid plaques. The findings, published in Alzheimer’s & Dementia, point to inflammation from the brain’s immune response as a possible contributor to sleep loss. The result is from mice and does not establish a treatment for people with Alzheimer’s.
Researchers at the University of Kentucky reported that temporarily removing most of the brain’s microglia restored more than two hours of sleep per day in mice with Alzheimer’s-like changes, even though amyloid plaques remained. The findings, published in Alzheimer’s & Dementia, suggest that inflammation linked to the brain’s immune response may contribute to sleep disruption in this disease model; they do not show that the approach works in people.
The research team studied genetically modified mice that develop amyloid plaques and compared them with wild-type mice. Animals were examined at six months, when plaques first appeared in the model, and at 18 months, when its Alzheimer’s-like pathology was more advanced. Researchers monitored sleep with devices recording brain activity through electroencephalography and muscle activity through electromyography, which together help distinguish sleep stages.
To test whether microglia were involved in the sleep changes, the researchers gave mice pexidartinib, also known as PLX3397, in their food for 14 days. The report says this depleted approximately 87% of microglia. Afterward, the treated mice slept longer and spent more time in deep sleep, with the total reported gain exceeding two hours per day. The improvement occurred without clearing the amyloid plaques.
The study also used light-sheet microscopy to map plaques and microglia in the brain. Its results, as described in the ScienceDaily report, distinguish the presence of plaques from the immune response to them: the plaques remained, while sleep improved after most microglia were depleted. That supports a role for microglia in this mouse model, but does not establish that they are the sole cause of sleep problems in Alzheimer’s.
Sleep Improved Despite Persistent Plaques
Sleep disruption is a major concern in Alzheimer’s disease, affecting patients and caregivers, and may complicate daily care. This study matters because it points to a possible contributor beyond plaque deposits themselves: inflammatory activity from microglia, the brain’s resident immune cells. If further work supports that pathway, it could broaden research into ways of addressing sleep symptoms without first removing plaques.
The result is an experimental finding, not a ready-to-use intervention. Depleting most microglia across the brain is a substantial biological manipulation, and the report does not establish its safety, duration of benefit, or suitability for people. Microglia also have normal roles in maintaining brain health. The study therefore identifies a research direction, not evidence that patients should take pexidartinib or seek to suppress their immune cells.
sleep tracking watch for older adults
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Sleep Link
Microglia help respond to injury and clear debris in the nervous system. The researchers propose that, in response to amyloid plaques, these cells may produce inflammatory signals that disrupt normal brain activity and sleep. This differs from an explanation focused mainly on plaques or damaged neurons: the study examines whether the brain’s response to plaques can itself add to the problem.
The experiments used a mouse model, not human participants. The team compared animals at two ages and used EEG and EMG to measure sleep alongside imaging to examine the distribution of plaques and microglia. According to the supplied ScienceDaily report, the work was led by Shannon L. Macauley, an associate professor at the University of Kentucky College of Medicine, with Nicholas J. Constantino as first author. The report says their paper appeared in Alzheimer’s & Dementia.
“Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia.”
— Shannon L. Macauley, University of Kentucky
comfortable blackout sleep mask for seniors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Effects Remain Unknown
The supplied report describes experiments in mice and does not provide evidence that depleting microglia improves sleep in people with Alzheimer’s. It also does not establish how long the sleep gains lasted, whether the effect can be produced safely, or what happened to other measures of brain function after treatment. The account gives the approximate proportion of microglia depleted and the treatment period, but does not specify the dose or provide a full assessment of adverse effects.
It is also unclear from the supplied material whether microglia are the main driver of sleep disruption across different forms or stages of human Alzheimer’s. The findings do not show that amyloid plaques are harmless or that plaque-related processes have no effect on sleep. They indicate that, in this model, sleep improved after microglia depletion while plaques remained.
white noise machine for bedroom sleep
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Tests Needed Before Translation
The next steps are to establish how the microglial response changes sleep, determine whether more targeted or temporary interventions can produce a similar result, and evaluate safety and longer-term effects in additional studies. Research would also need to test whether the same relationship appears in people before any treatment claim could be made.
The ScienceDaily report identifies the study and its publication but does not specify a planned human trial or a timetable for follow-up research. For now, the finding is best understood as evidence from an Alzheimer’s-like mouse model that sleep may improve without plaque clearance under this experimental condition.
Alzheimer's caregiver sleep and dementia care books
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Did the researchers restore sleep in people with Alzheimer’s?
No. The report describes experiments in mice with Alzheimer’s-like brain changes. It does not report a human trial or show that the approach improves sleep in patients.
How much sleep did the mice regain?
The researchers reported that treated mice gained more than two hours of sleep per day and spent more time in deep sleep. The result applies to the mouse experiment, not to people.
Were the amyloid plaques removed?
No. The reported sleep improvement followed depletion of most microglia, while the amyloid plaques remained.
What did the researchers use to deplete microglia?
They gave mice pexidartinib (PLX3397) in their food for 14 days. The report says approximately 87% of microglia were depleted. It does not establish that this is safe or appropriate for treating sleep problems in people.
No. The findings support a role for microglia in sleep disruption in this specific mouse model. They do not show that microglia are the sole cause in mice or people, or that the same effect occurs across Alzheimer’s disease in humans.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
